Literature DB >> 21750969

Suppression of interleukin-17-producing T-helper 17 cells by retinal pigment epithelial cells.

Sunao Sugita1, Shintaro Horie2, Yukiko Yamada2, Yuko Kawazoe2, Hiroshi Takase2, Manabu Mochizuki2.   

Abstract

PURPOSE: To determine whether retinal pigment epithelial (RPE) cells can inhibit cytokine production by activated T helper (Th) cells.
METHODS: Primary RPE cells were cultured from normal C57BL/6 mice. Target bystander T cells were established from normal splenic T cells with anti-CD3 antibodies. T-cell activation was assessed for production of cytokines, determined by ELISA. Production of IL-17 on target T cells was evaluated using oligonucleotide microarray, RT-PCR and flow cytometry. TGFβ small interfering RNA was used to inhibit the RPE cells' inhibitory function.
RESULTS: The cultured RPE cells greatly suppressed the activation of bystander CD4(+) T cells in vitro, especially cytokine production by target T helper cells (Th1 cells, Th2 cells and Th17 cells, but not Th3 cells). The cultured RPE cells and RPE supernatants significantly suppressed the IL-17-producing CD4(+) T cells and fully suppressed the polarized Th17 cell lines that were induced by recombinant proteins IL-6 and TGFβ2. However, the RPE cells failed to suppress the IL-17-producing T cells in the presence of rIL-6. In addition, the TGFβ produced by the RPE cells suppressed the Th17 cells.
CONCLUSIONS: These results indicate that RPE cells have an immunosuppressive effect on Th17-type effector T cells, which highlights a role for ocular resident cells in establishing immune regulation in the eye.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21750969     DOI: 10.1007/s10384-011-0064-9

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  40 in total

1.  Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals.

Authors:  S R Thurau; C C Chan; R B Nussenblatt; R R Caspi
Journal:  Clin Exp Immunol       Date:  1997-08       Impact factor: 4.330

2.  Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype.

Authors:  D Avichezer; P B Silver; C C Chan; B Wiggert; R R Caspi
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-01       Impact factor: 4.799

3.  Association of CD4+ CD25+ T cells with prevention of severe destructive arthritis in Borrelia burgdorferi-vaccinated and challenged gamma interferon-deficient mice treated with anti-interleukin-17 antibody.

Authors:  Dean T Nardelli; Matthew A Burchill; Douglas M England; Jose Torrealba; Steven M Callister; Ronald F Schell
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

4.  IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease.

Authors:  Wei Chi; Peizeng Yang; Bing Li; Changyou Wu; Haoli Jin; Xuefei Zhu; Lina Chen; Hongyan Zhou; Xiangkun Huang; Aize Kijlstra
Journal:  J Allergy Clin Immunol       Date:  2007-03-01       Impact factor: 10.793

5.  Aqueous humor contains transforming growth factor-beta and a small (less than 3500 daltons) inhibitor of thymocyte proliferation.

Authors:  R D Granstein; R Staszewski; T L Knisely; E Zeira; R Nazareno; M Latina; D M Albert
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

6.  Role of thrombospondin-1 in T cell response to ocular pigment epithelial cells.

Authors:  Yuri Futagami; Sunao Sugita; Jose Vega; Kazuhiro Ishida; Hiroshi Takase; Kazuichi Maruyama; Hiroyuki Aburatani; Manabu Mochizuki
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

7.  Participation of pigment epithelium in ocular immune privilege. 3. Epithelia cultured from iris, ciliary body, and retina suppress T-cell activation by partially non-overlapping mechanisms.

Authors:  Kazuhiro Ishida; Noorjahan Panjwani; Zhiyi Cao; J Wayne Streilein
Journal:  Ocul Immunol Inflamm       Date:  2003-06       Impact factor: 3.070

8.  Acquisition of T regulatory function in cathepsin L-inhibited T cells by eye-derived CTLA-2alpha during inflammatory conditions.

Authors:  Sunao Sugita; Shintaro Horie; Orie Nakamura; Kazuichi Maruyama; Hiroshi Takase; Yoshihiko Usui; Masaru Takeuchi; Kazumi Ishidoh; Masato Koike; Yasuo Uchiyama; Christoph Peters; Yoshimi Yamamoto; Manabu Mochizuki
Journal:  J Immunol       Date:  2009-10-15       Impact factor: 5.422

9.  Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis.

Authors:  Takeru Yoshimura; Koh-Hei Sonoda; Nobuyuki Ohguro; Yoshiyuki Ohsugi; Tatsuro Ishibashi; Daniel J Cua; Takashi Kobayashi; Hiroki Yoshida; Akihiko Yoshimura
Journal:  Rheumatology (Oxford)       Date:  2009-01-22       Impact factor: 7.580

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  4 in total

1.  Elevated serum levels of interleukin-17A in uveitis patients.

Authors:  Shayma Jawad; Baoying Liu; Elvira Agron; Robert B Nussenblatt; H Nida Sen
Journal:  Ocul Immunol Inflamm       Date:  2013-08-19       Impact factor: 3.070

2.  Thioredoxin Interacting Protein (TXNIP) and Pathogenesis of Diabetic Retinopathy.

Authors:  Lalit P Singh
Journal:  J Clin Exp Ophthalmol       Date:  2013-08-05

Review 3.  Immunopathogenic Background of Pars Planitis.

Authors:  Joanna Przeździecka-Dołyk; Agnieszka Węgrzyn; Anna Turno-Kręcicka; Marta Misiuk-Hojło
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-10-05       Impact factor: 4.291

4.  SARS-CoV-2 infects and replicates in photoreceptor and retinal ganglion cells of human retinal organoids.

Authors:  Yotam Menuchin-Lasowski; André Schreiber; Aarón Lecanda; Angeles Mecate-Zambrano; Linda Brunotte; Olympia E Psathaki; Stephan Ludwig; Thomas Rauen; Hans R Schöler
Journal:  Stem Cell Reports       Date:  2022-03-24       Impact factor: 7.294

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.